Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults

Go back to Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults
(NASDAQ: OSMT) Delayed: 1.11 --0 (-0%)
Previous Close $1.11    52 Week High
Open $1.11    52 Week Low
Day High $1.11    P/E N/A 
Day Low $1.11    EPS
Volume 3,485